Theravance Inc news

   Watch this stock
Showing stories 1 - 7 of about 7   

Articles published

THRX 9.16 -0.12 (-1.29%)
price chart
Theravance licenses antibiotic tech to Hospira
Biopharmaceutical company Theravance Inc said it licensed its technology to manufacture antibiotic Vibativ to specialty medicines maker Hospira Inc. The company would purchase from Hospira more than a majority of its Vibativ 750 mg dosage form ...
GlaxoSmithKline boosts Theravance stake
Following approval Tuesday by Theravance stockholders, GSK's previously announced acquisition of 10 million shares of Theravance is now complete - meaning GSK owns 25.8 million shares of Theravance common stock. That's 26.7 percent of the total ...
AutoCanada shares hit five-year high on news of GM deal
Shares of Edmonton-based AutoCanada Inc. (TSX:ACQ) soared to the highest level in nearly five years Wednesday after it announced a deal late Tuesday to acquire a stake in a General Motors dealership in suburban Sherwood Park.
Tracking Seth Klarman's Baupost Group Holdings: Q1 2012 Update
Theravance Inc (NASDAQ:THRX): THRX, approximately 10% of the US long portfolio position, was increased marginally this quarter.
Seth Klarman Betting Big On These 2 Stocks
Seth Klarman's Baupost Group is one of the largest hedge funds and regarded very highly in the world of "Graham-Dodd" value investors.
Auxilium-Glaxo to Drive Testim Sales
Specialty biopharmaceutical company, Auxilium Pharmaceuticals, Inc. recently entered into a co-promotion agreement with GlaxoSmithKline plc's (GSK - Analyst Report) U.S.
Biopharma raising $500K eyes competitive asthma/COPD drug market
Recent U.S. Food and Drug Administration approvals have included Merck's combination drug Dulera, Novartis/Genentech's Xolair and Novartis/Schering-Plough's Foradil, plus a new nondrug treatment called bronchial thermoplasty.